<DOC>
	<DOCNO>NCT01916720</DOCNO>
	<brief_summary>The primary objective determine Lp-PLA2 activity atherosclerotic carotid plaque 14 ( +/-4 ) day treatment darapladib , compare placebo . Secondary objective include determination change Lp-PLA2 activity blood , Lp-PLA2 mass blood plaque , specify biomarkers blood plaque respective correlation 's Lp-PLA2 . In addition , study aim characterise PK/PD repeat oral dose SB-480848 , safety tolerability population .</brief_summary>
	<brief_title>Study Determine Effect 14 Days Dosing With Darapladib ( SB-480848 ) Carotid Plague Composition Patients With Planned Carotid Endarterectomy</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<criteria>Male female , &gt; 35 year age Females childbearing potential must use approved contraceptive measure Male patient must willing abstain sexual intercourse use form contraception engage sexual intercourse woman could become pregnant Planned carotid endarterectomy within timeframe compatible recruitment study able comply requirement study , deem investigator Written , inform consent participate Recent myocardial infarction ( within previous 4 week ) Currently take corticosteroid , warfarin , digoxin potent CYP3A4 inhibitor Recent ( &lt; 3 month ) ongoing acute infection significant trauma associate bruise and/or take antibiotic . Prophylactic antibiotic surgery allow Change dose lipidlowering therapy previous 4 week randomisation History chronic liver disease ( e.g . cirrhosis , hepatitis ) OR ALT OR AST â‰¥1.5 time upper limit normal ( ULN ) screen Diagnosis systemic lupus erythematosis ( SLE ) rheumatoid arthritis ( RA ) Clinically significant anaemia History severe renal impairment ( serum creatinine &gt; 1.8mg/dL ) Unstable angina History asthma , anaphylaxis anaphylactoid reaction , severe allergic response Abuse alcohol drug within last 6 month Any factor clinical disease state , investigator 's opinion , would preclude completion safe surgical procedure and/or completion study Use investigational drug within 30 day 5 halflives last dose prior start study , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>